{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T08:34:04Z","timestamp":1776587644985,"version":"3.51.2"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T00:00:00Z","timestamp":1693785600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T00:00:00Z","timestamp":1693785600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Health Innovation Special Project of Hebei Provice Key R&D Program","award":["22377704D"],"award-info":[{"award-number":["22377704D"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Gastric cancer (CC) is a disease with high incidence and mortality rate. Immunotherapy is an important method for gastric cancer while lack of effective predictor. Integrins play an important role in the development. We aimed to explore the predictive value of \u03b21 integrin (ITGB1) as a predictor of immunnotherapy in gastric cancer.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Differential expression analysis was conducted using the Gene Expression Profiling Interactive Analysis (GEPIA) 2.0 and GEO databases. GEPIA data were used to evaluate the prognostic value of ITGB1 in gastric cancer (GC). Transcriptomic and clinical data of GC and normal tissues were downloaded from The Cancer Genome Atlas database, and the TIMER database was used to evaluate the association between ITGB1 and immune infiltration. Time-dependent receiver operating characteristic (ROC) curve analysis was used to determine the prognostic value of ITGB1. To verify ITGB1 expression at the protein level, immunohistochemical staining was conducted. In addition, to analyze the correlation of ITGB1 with PD-1 and PD-L1, we examined levels of PD-1 and PD-L1 by IHC and determined the predictive value of ITGB1 for anti-PD-1 therapy in GC by ROC curve analysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Compared with normal tissues, analysis of GEPIA and data at protein levels showed significantly higher expression of ITGB1 in GC. In addition, higher expression of ITGB1 was associated with worse pathological G-staging and tumor T-staging, which suggested that ITGB1 is a risk factor for poor prognosis in GC. The level of ITGB1 expression was positively correlated with CD8\u2009+\u2009T cells, neutrophils, macrophages, and dendritic cells. ITGB1 expression was also correlated with PD-L1 expression, and this was further verified at the protein level by immunohistochemical analysis. The area under the ROC curve was 0.808.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>ITGB1 may be a promising prognostic biomarker and effective predictor for anti-PD-1 therapy in GC.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>Retrospectively registered.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12876-023-02930-0","type":"journal-article","created":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T15:02:19Z","timestamp":1693839739000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Evaluation of ITGB1 expression as a predictor of the therapeutic effects of immune checkpoint inhibitors in gastric cancer"],"prefix":"10.1186","volume":"23","author":[{"given":"Chao","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Li","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui-Qing","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,9,4]]},"reference":[{"issue":"3","key":"2930_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"2930_CR2","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1002\/ags3.12439","volume":"5","author":"K Yamashita","year":"2021","unstructured":"Yamashita K, Hosoda K, Niihara M, Hiki N. History and emerging trends in chemotherapy for gastric cancer. Ann Gastroenterol Surg. 2021;5(4):446\u201356.","journal-title":"Ann Gastroenterol Surg"},{"issue":"3","key":"2930_CR3","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S1470-2045(08)70035-4","volume":"9","author":"W Koizumi","year":"2008","unstructured":"Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama W, Toh Y, Nagaie T, Takagi S, Yamamura Y, Yanaoka K, Orita H, Takeuchi M. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9(3):215\u201321.","journal-title":"Lancet Oncol"},{"issue":"5","key":"2930_CR4","doi-asserted-by":"publisher","first-page":"491","DOI":"10.2217\/fon-2020-0737","volume":"17","author":"HC Chung","year":"2021","unstructured":"Chung HC, Bang YJ, Fuchs CS, Qin SK, Satoh T, Shitara K, Tabernero J, Cutsem EV, Alsina M, Cao ZA, Lu J, Bhagia P, Shih CS, Janjigian YY. First-line pembrolizumab\/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811. Future Oncol. 2021;17(5):491\u2013501.","journal-title":"Future Oncol"},{"issue":"11","key":"2930_CR5","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","volume":"15","author":"H Wilke","year":"2014","unstructured":"Wilke H, Muro K, Cutsem EV, Oh SC, Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov O, Kim TY, Cunningham D, Rougier P, Komatsu Y, Ajani J, Emig M, Carlesi R, Ferry D, Chandrawansa K, Schwartz JD, Ohtsu A, RAINBOW Study Group. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a doubleblind, randomised phase 3 trial. Lancet Oncol. 2014;15(11):1224\u201335.","journal-title":"Lancet Oncol"},{"issue":"2","key":"2930_CR6","doi-asserted-by":"publisher","first-page":"188615","DOI":"10.1016\/j.bbcan.2021.188615","volume":"1876","author":"KX Li","year":"2021","unstructured":"Li KX, Zhang A, Li XY, Zhang HT, Zhao LM. Advances in clinical immunotherapy for gastric cancer. Biochim Biophys Acta Rev Cancer. 2021;1876(2):188615.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"4","key":"2930_CR7","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, Savage KJ, Hernberg MM, Lebb\u00e9 C, Charles J, Mihalcioiu C, Chiarion-Sileni V, Mauch C, Cognetti F, Arance A, Schmidt H, Schadendorf D, Gogas H, Lundgren-Eriksson L, Horak C, Sharkey B, Waxman IM, Atkinson V, Ascierto PA. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320\u201330.","journal-title":"N Engl J Med"},{"issue":"19","key":"2930_CR8","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Abreu DR, Robinson AG, Hui R, Cs\u0151szi T, F\u00fcl\u00f6p A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O\u2019Brien M, Rao S, Hotta K, Leiby MA, Lubiniecki GM, Yue S, Rangwala R, Brahmer JR, KEYNOTE-024 Investigators. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823\u201333.","journal-title":"N Engl J Med"},{"issue":"10027","key":"2930_CR9","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","volume":"387","author":"RS Herbst","year":"2016","unstructured":"Herbst RS, Baas P, Kim DW, Felip E, Gracia JLP, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, Majem M, Fidler MJ, de Castro G Jr, Garrido M, Lubiniecki GM, Yue S, Ellie IM, Marisa DF, Garon EB. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540\u201350.","journal-title":"Lancet"},{"issue":"19","key":"2930_CR10","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Choueiri TK, Gurney H, Donskov F, Bono P, Wagstaff J, Gauler TC, Ueda T, Tomita Y, Schutz FA, Kollmannsberger C, Larkin J, Ravaud A, Simon JS, Xu LA, Waxman IM, Sharma P, CheckMate 025 Investigators. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803\u201313.","journal-title":"N Engl J Med"},{"issue":"4","key":"2930_CR11","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252\u201364.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"2930_CR12","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1093\/jjco\/hyaa202","volume":"51","author":"A Kawazoe","year":"2021","unstructured":"Kawazoe A. Current status of immunotherapy for advanced gastric cancer. Japanese J Clin Oncol. 2021;51(1):20\u20137.","journal-title":"Japanese J Clin Oncol"},{"issue":"3","key":"2930_CR13","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nri.2017.108","volume":"18","author":"AH Sharpe","year":"2018","unstructured":"Sharpe AH, Pauken KE. The diverse functions of the PD1 inhibitory pathway. Nat Rev Immunol. 2018;18(3):153\u201367.","journal-title":"Nat Rev Immunol"},{"key":"2930_CR14","doi-asserted-by":"publisher","first-page":"920512","DOI":"10.3389\/fimmu.2022.920512","volume":"13","author":"JQ Song","year":"2022","unstructured":"Song JQ, Wei RY, Huo SY, Gao JP, Liu XW. Metastasis related epithelial-mesenchymal transition signature predicts prognosis and response to immunotherapy in gastric cancer. Front Immunol. 2022;13:920512.","journal-title":"Front Immunol"},{"issue":"6","key":"2930_CR15","doi-asserted-by":"publisher","first-page":"2236","DOI":"10.3892\/ijo.2016.3480","volume":"48","author":"C Wu","year":"2016","unstructured":"Wu C, Zhuang Y, Jiang S, Liu SL, Zhou JY, Wu J, Teng YH, Xia BM, Wang RP, Zou X. Interaction between Wnt\/beta-catenin pathway and microRNAs regulates epithelial-mesenchymal transition in gastric cancer (Review). Int J Oncol. 2016;48(6):2236\u201346.","journal-title":"Int J Oncol"},{"key":"2930_CR16","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.semcancer.2016.08.009","volume":"42","author":"G Cantelli","year":"2017","unstructured":"Cantelli G, Crosas-Molist E, Georgouli M, Sanz-Moreno V. TGF\u03b2-in-duced transcription in cancer. Semin Cancer Biol. 2017;42:60\u20139.","journal-title":"Semin Cancer Biol"},{"issue":"9","key":"2930_CR17","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1038\/onc.2012.126","volume":"32","author":"HX Zheng","year":"2013","unstructured":"Zheng HX, Cai YD, Wang YD, Cui XB, Xie TT, Li WJ, Peng L, Zhang Y, Wang ZQ, Wang J, Jiang B. Fas signaling promotes motility and metastasis through epithelial-mesenchymal transition in gastrointestinal cancer. Oncogene. 2013;32(9):1183\u201392.","journal-title":"Oncogene"},{"issue":"12","key":"2930_CR18","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.1016\/j.ejca.2013.03.014","volume":"49","author":"HX Zheng","year":"2013","unstructured":"Zheng HX, Li WJ, Wang YD, Liu ZZ, Cai YD, Xie TT, Shi M, Wang ZQ, Jiang B. Glycogen synthase kinase3 beta regulates Snail and beta-catenin expression during Fas-induced epithelial-mesenchymal transition in gastrointestinal cancer. Eur J Cancer. 2013;49(12):2734\u201346.","journal-title":"Eur J Cancer"},{"issue":"3","key":"2930_CR19","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/nrm3758","volume":"15","author":"S Lamouille","year":"2014","unstructured":"Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesechymal transition. Nat Rev Mol Cell Biol. 2014;15(3):178\u201396.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2930_CR20","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.canlet.2019.10.013","volume":"468","author":"YY Jiang","year":"2020","unstructured":"Jiang YY, Zhan HX. Communication between EMT and PD-L1 signaling: new insights into tumor immune evasion. Cancer Lett. 2020;468:72\u201381.","journal-title":"Cancer Lett"},{"issue":"1","key":"2930_CR21","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1186\/s12935-021-02380-2","volume":"21","author":"BQ Qiu","year":"2021","unstructured":"Qiu BQ, Lin XH, Lai SQ, Lu F, Lin K, Long X, Zhu SQ, Zou HX, Xu JJ, Liu JC, Wu YB. ITGB1-DT\/ARNTL2 axis may be a novel biomarker in lung adenocarcinoma: a bioinformatics analysis and experimental validation. Cancer Cell Int. 2021;21(1):665.","journal-title":"Cancer Cell Int"},{"issue":"1","key":"2930_CR22","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1080\/21655979.2020.1857120","volume":"12","author":"X Wang","year":"2021","unstructured":"Wang X, Li TZ. Ropivacaine inhibits the proliferation and migration of colorectal cancer cells through ITGB1. Bioengineered. 2021;12(1):44\u201353.","journal-title":"Bioengineered"},{"issue":"22","key":"2930_CR23","doi-asserted-by":"publisher","first-page":"13481","DOI":"10.1111\/jcmm.15990","volume":"24","author":"HK Zhuang","year":"2020","unstructured":"Zhuang HK, Zhou ZX, Ma ZY, Li ZC, Liu CS, Huang SZ, Zhang CZ, Hou BH. Characterization of the prognostic and oncologic values of ITGB superfamily members in pancreatic cancer. J Cell Mol Med. 2020;24(22):13481\u201393.","journal-title":"J Cell Mol Med"},{"issue":"2","key":"2930_CR24","doi-asserted-by":"publisher","first-page":"635","DOI":"10.7150\/ijbs.52319","volume":"17","author":"YX Li","year":"2021","unstructured":"Li YX, Sun C, Tan YG, Zhang HY, Li YC, Zou HW. ITGB1 enhances the radioresistance of human non-small cell lung cancer cells by modulating the DNA damage response and YAP1-induced epithelial-mesenchymal transition. Int J Biol Sci. 2021;17(2):635\u201350.","journal-title":"Int J Biol Sci"},{"issue":"14","key":"2930_CR25","doi-asserted-by":"publisher","first-page":"19064","DOI":"10.18632\/aging.203355","volume":"13","author":"YL Lv","year":"2021","unstructured":"Lv YL, Shan YJ, Song LN, Zhao YF, Lai RX, Su JY, Zhang XY. Type I collagen promotes tumor progression of integrin \u03b21 positive gastric cancer through a BCL9L\/\u03b2-catenin signaling pathway. Aging. 2021;13(14):19064\u201376.","journal-title":"Aging"},{"key":"2930_CR26","doi-asserted-by":"publisher","first-page":"693881","DOI":"10.3389\/fimmu.2021.693881","volume":"12","author":"TT Wu","year":"2021","unstructured":"Wu TT, Tang CJ, Tao RC, Yong XZ, Jiang QZ, Feng C. PD-L1-mediated immunosuppression in oral squamous cell carcinoma: relationship with macrophage infiltration and epithelial to mesenchymal transition markers. Front Immuno. 2021;12:693881.","journal-title":"Front Immuno"},{"issue":"1","key":"2930_CR27","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/s41392-022-01136-2","volume":"7","author":"D Wang","year":"2022","unstructured":"Wang D, Wu X, Sun Y. Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response. Signal Transduct Target Ther. 2022;7(1):331.","journal-title":"Signal Transduct Target Ther"},{"key":"2930_CR28","doi-asserted-by":"publisher","first-page":"680369","DOI":"10.3389\/fgene.2021.680369","volume":"12","author":"Y Wei","year":"2021","unstructured":"Wei Y, Chen X, Ren X, Wang B, Zhang Q, Bu H, Qian J, Shao P. Identification of MX2 as a novel prognostic biomarker for sunitinib resistance in clear cell renal cell carcinoma. Front Genet. 2021;12:680369.","journal-title":"Front Genet"},{"key":"2930_CR29","doi-asserted-by":"publisher","first-page":"627508","DOI":"10.3389\/fgene.2021.627508","volume":"12","author":"SL Jiang","year":"2021","unstructured":"Jiang SL, Ren XH, Liu SY, Lu ZW, Xu AM, Qin C, Wang ZJ. Integrated analysis of the prognosis-associated rna-binding protein genes and candidate drugs in renal papillary cell carcinoma. Front Genet. 2021;12:627508.","journal-title":"Front Genet"},{"issue":"1","key":"2930_CR30","doi-asserted-by":"publisher","first-page":"4272","DOI":"10.1038\/s41598-022-07070-1","volume":"12","author":"YQ Liu","year":"2022","unstructured":"Liu YQ, Wang JW, Li L, Qin HB, Wei Y, Zhang X, Ren XH, Ding W, Shen XD, Li GY, Lu ZW, Zhang D, Qin C, Tao LS, Chen XL. AC010973.2 promotes cell proliferation and is one of six stemness-related genes that predict overall survival of renal clear cell carcinoma. Sci Rep. 2022;12(1):4272.","journal-title":"Sci Rep"},{"issue":"1","key":"2930_CR31","doi-asserted-by":"publisher","first-page":"8069","DOI":"10.1038\/s41598-021-87540-0","volume":"11","author":"DJ Wu","year":"2021","unstructured":"Wu DJ, Yin ZH, Ji YS, Li L, Li YX, Meng FQ, Ren XH, Xu M. Identifcation of novel autophagy-related lncRNAs associated with a poor prognosis of colon adenocarcinoma through bioinformatics analysis. Sci Rep. 2021;11(1):8069.","journal-title":"Sci Rep"},{"key":"2930_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.lungcan.2019.10.012","volume":"139","author":"JC Thompson","year":"2020","unstructured":"Thompson JC, Hwang WT, Davis C, Deshpande C, Jeffries S, Rajpurohit Y, Krishna V, Smirnov D, Verona R, Lorenzi MV, Langer CJ, Albelda SM. Gene signatures of tumor inflammation and Epithelial-to-Mesenchymal Transition (EMT) predict responses to immune checkpoint blockade in lung cancer with high accuracy. Lung Cancer. 2020;139:1\u20138.","journal-title":"Lung Cancer"},{"issue":"3","key":"2930_CR33","doi-asserted-by":"publisher","first-page":"543","DOI":"10.3390\/biomedicines10030543","volume":"10","author":"S Choi","year":"2022","unstructured":"Choi S, Park S, Kim H, Kang SY, Ahn S, Kim KM. Gastric cancer: mechanisms, biomarkers, and therapeutic approaches. Biomedicines. 2022;10(3):543.","journal-title":"Biomedicines"},{"issue":"1","key":"2930_CR34","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13104-019-4163-x","volume":"12","author":"SH Sohn","year":"2019","unstructured":"Sohn SH, Kim B, Sul HJ, Kim YJ, Kim HS, Kim HT, Seo JB, Koh Y, Zang DY. INC280 inhibits Wnt\/\u03b2-catenin and EMT signaling pathways and its induce apoptosis in diffuse gastric cancer positive for c-MET amplification. BMC Res Notes. 2019;12(1):125.","journal-title":"BMC Res Notes"},{"issue":"17","key":"2930_CR35","doi-asserted-by":"publisher","first-page":"17167","DOI":"10.18632\/aging.103667","volume":"12","author":"J Fang","year":"2020","unstructured":"Fang J, Ding Z. SNAI1 is a prognostic biomarker and correlated with immune infiltrates in gastrointestinal cancers. Aging (Albany NY). 2020;12(17):17167.","journal-title":"Aging (Albany NY)"},{"issue":"7","key":"2930_CR36","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/s41580-018-0007-0","volume":"19","author":"CJ David","year":"2018","unstructured":"David CJ, Massagu\u00e9 J. Contextual determinants of TGF\u03b2 action in development, immunity and cancer. Nat Rev Mol Cell Bio. 2018;19(7):419\u201335.","journal-title":"Nat Rev Mol Cell Bio"},{"issue":"1","key":"2930_CR37","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1186\/s12876-022-02257-2","volume":"22","author":"N Kang","year":"2022","unstructured":"Kang N, Xie X, Zhou X, Wang Y, Chen S, Qi R, Liu T, Jiang H. Identification and validation of EMT-immune-related prognostic biomarkers CDKN2A, CMTM8 and ILK in colon cancer. BMC Gastroenterol. 2022;22(1):190.","journal-title":"BMC Gastroenterol"},{"key":"2930_CR38","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3389\/fonc.2015.00003","volume":"5","author":"J Johansson","year":"2015","unstructured":"Johansson J, Tabor V, Wikell A, Jalkanen S, Fuxe J. TGF-\u03b21-induced Epithelial-mesenchymal transition promotes monocyte\/macrophage properties in breast cancer cells. Front Oncol. 2015;5:3.","journal-title":"Front Oncol"},{"issue":"32","key":"2930_CR39","doi-asserted-by":"publisher","first-page":"e11769","DOI":"10.1097\/MD.0000000000011769","volume":"97","author":"JS Lee","year":"2018","unstructured":"Lee JS, Won HS, Sun DS, Hong JH, Ko YH. Prognostic role of tumor-infiltrating lymphocytes in gastric cancer: A systematic review and meta-analysis. Medicine (Baltimore). 2018;97(32):e11769.","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"2930_CR40","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1007\/s10120-021-01239-9","volume":"25","author":"J Figueiredo","year":"2022","unstructured":"Figueiredo J, Ferreira RM, Xu H, Gon\u00e7alves M, Carvalho AB, Cravo J, Maia AF, Carneiro P, Figueiredo C, Smith ML, Stamenovi\u0107 D, Morais-de-S\u00e1 E, Seruca R. Integrin \u03b21 orchestrates the abnormal cell-matrix attachment and invasive behaviour of E-cadherin dysfunctional cells. Gastric Cancer. 2022;25(1):124\u201337.","journal-title":"Gastric Cancer"},{"issue":"2","key":"2930_CR41","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1002\/cam4.5042","volume":"12","author":"W Gu","year":"2023","unstructured":"Gu W, Sun H, Zhang M, Mo S, Tan C, Ni S, Yang Z, Wang Y, Sheng W, Wang L. ITGB1 as a prognostic biomarker correlated with immune suppression in gastric cancer. Cancer Med. 2023;12(2):1520\u201331.","journal-title":"Cancer Med"},{"issue":"14","key":"2930_CR42","doi-asserted-by":"publisher","first-page":"19064","DOI":"10.18632\/aging.203355","volume":"13","author":"Y Lv","year":"2021","unstructured":"Lv Y, Shan Y, Song L, Zhao Y, Lai R, Su J, Zhang X. Type I collagen promotes tumor progression of integrin \u03b21 positive gastric cancer through a BCL9L\/\u03b2-catenin signaling pathway. Aging (Albany NY). 2021;13(14):19064\u201376.","journal-title":"Aging (Albany NY)"},{"issue":"5","key":"2930_CR43","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1083\/jcb.200312172","volume":"165","author":"JP Annes","year":"2004","unstructured":"Annes JP, Chen Y, Munger JS, Rifkin DB. Integrin alphaVbeta6-mediated activation of latent TGF-beta requires the latent TGF-beta binding protein-1. J Cell Biol. 2004;165(5):723\u201334.","journal-title":"J Cell Biol"},{"key":"2930_CR44","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3389\/fimmu.2019.00071","volume":"10","author":"D Zhang","year":"2019","unstructured":"Zhang D, He W, Wu C, Tan Y, He Y, Xu B, Chen L, Li Q, Jiang J. Scoring system for tumor-infiltrating lymphocytes and its prognostic value for gastric cancer. Front Immunol. 2019;10:71.","journal-title":"Front Immunol"},{"issue":"8","key":"2930_CR45","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1158\/1078-0432.CCR-15-1507","volume":"22","author":"PS Hegde","year":"2016","unstructured":"Hegde PS, Karanikas V, Evers S. The where, the when, and the how of immune monitoring for cancer immunotherapies in the era of checkpoint inhibition. Clin Cancer Res. 2016;22(8):1865\u201374.","journal-title":"Clin Cancer Res"},{"issue":"7637","key":"2930_CR46","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature21349","volume":"541","author":"DS Chen","year":"2017","unstructured":"Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541(7637):321\u201330.","journal-title":"Nature"},{"issue":"7693","key":"2930_CR47","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang YL, Kadel EE III, Koeppen H, Astarita JL, Cubas R, Jhunjhunwala S, Banchereau R, Yang Y, Guan YH, Chalouni C, Ziai J, \u015eenbabao\u011flu Y, Santoro S, Sheinson D, Hung J, Giltnane JM, Pierce AA, Mesh K, Lianoglou S, Riegler J, Carano R, Eriksson P, H\u00f6glund M, Somarriba L, Halligan DL, Heijden M, Loriot Y, Rosenberg JE, Fong L, Mellman I, Chen DS, Green M, Derleth C, Fine G, Hegde PS, Bourgon R, Powles T. TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018;554(7693):544\u20138.","journal-title":"Nature"},{"issue":"3","key":"2930_CR48","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1007\/s12094-021-02714-6","volume":"24","author":"H Kim","year":"2022","unstructured":"Kim H, Heo YJ, Cho YA, Kang SY, Ahn S, Kim KM. Tumor immune microenvironment is influenced by frameshift mutations and tumor mutational burden in gastric cancer. Clin Transl Oncol. 2022;24(3):556\u201367.","journal-title":"Clin Transl Oncol"},{"key":"2930_CR49","doi-asserted-by":"crossref","unstructured":"Wang H, Rong J, Zhao Q, Song C, Zhao R, Chen S, Xie Y. Identification and Validation of Immune Cells and Hub Genes in Gastric Cancer Microenvironment. Dis Markers. 2022;2022:8639323.\u00a0https:\/\/www.hindawi.com\/journals\/dm\/2022\/8639323\/,\u00a0https:\/\/pubmed.ncbi.nlm.nih.gov\/35422890\/.","DOI":"10.1155\/2022\/8639323"},{"issue":"5","key":"2930_CR50","doi-asserted-by":"publisher","first-page":"e180013","DOI":"10.1001\/jamaoncol.2018.0013","volume":"4","author":"CS Fuchs","year":"2018","unstructured":"Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, Sun WJ, Jalal SI, Shah MA, Metges JP, Garrido M, Golan T, Mandala M, Wainberg ZA, Catenacci DV, Ohtsu A, Shitara K, Geva R, Bleeker J, Ko AH, Ku G, Philip P, Enzinger PC, Bang YJ, Levitan D, Wang JD, Rosales M, Dalal RP, Yoon HH. Safety and effificacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 Trial. JAMA Oncol. 2018;4(5):e180013.","journal-title":"JAMA Oncol"},{"issue":"10294","key":"2930_CR51","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, Wyrwicz L, Yamaguchi K, Skoczylas T, Bragagnoli AC, Liu TS, Schenker M, Yanez P, Tehfe M, Kowalyszyn R, Karamouzis MV, Bruges R, Zander T, Cid RP, Hitre E, Feeney K, Cleary JM, Poulart V, Cullen D, Lei M, Xiao H, Kondo K, Li MS, Ajani JA. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastrooesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398(10294):27\u201340.","journal-title":"Lancet"},{"key":"2930_CR52","doi-asserted-by":"publisher","first-page":"958070","DOI":"10.3389\/fphar.2022.958070","volume":"13","author":"X Zhang","year":"2022","unstructured":"Zhang X, Li Y, Hu P, Xu L, Qiu H. Identification of molecular patterns and prognostic models of epithelial-mesenchymal transition and immune-combined index in the gastric cancer. Front Pharmacol. 2022;13:958070.","journal-title":"Front Pharmacol"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-023-02930-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-023-02930-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-023-02930-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T21:32:12Z","timestamp":1700429532000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-023-02930-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,4]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2930"],"URL":"https:\/\/doi.org\/10.1186\/s12876-023-02930-0","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,4]]},"assertion":[{"value":"19 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was obtained by the Ethics Committee of Handan Central Hospital and certify that the study was performed in accordance with the ethical standards as laid down in the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"298"}}